Clinical characteristics and mortality according to troponin dynamic changes
| hs-cTnI dynamic changes | P value | ||
| Yes (n=90) | No (n=264) | ||
| Age >70 years, n (%) | 65 (72.2) | 138 (52.3) | 0.001 |
| Male, n (%) | 44 (48.9) | 163 (61.7) | 0.033 |
| Vascular risk factors | |||
| Hypertension, n (%) | 62 (68.9) | 168 (63.6) | 0.367 |
| Diabetes mellitus, n (%) | 24 (26.7) | 74 (28.0) | 0.803 |
| Current smoking, n (%) | 11 (12.2) | 47 (17.8) | 0.217 |
| Comorbidities | |||
| AF, n (%) | 56 (62.2) | 123 (46.6) | 0.010 |
| CAD, n (%) | 15 (16.7) | 24 (9.1) | 0.047 |
| Previous stroke, n (%) | 19 (21.1) | 43 (16.3) | 0.299 |
| Treatment status | |||
| Previous antithrombotic therapy, n (%) | 22 (24.4) | 40 (15.2) | 0.045 |
| OTA, min (IQR) | 89 (57–224) | 107 (60–240) | 0.549 |
| Transfers, n (%) | 9 (10) | 39 (14.8) | 0.253 |
| Use of IV rtPA, n (%) | 21 (23.3) | 73 (27.7) | 0.423 |
| Poor reperfusion, n (%) | 22 (24.4) | 43 (16.3) | 0.084 |
| Dual antiplatelet therapy, n (%) | 5 (5.6) | 36 (13.6) | 0.039 |
| NIHSS on admission | 0.001 | ||
| 0–8*, n (%) | 3 (3.3) | 42 (15.9) | |
| 9–16, n (%) | 29 (32.2) | 103 (39.0) | 0.021† |
| >16, n (%) | 58 (64.4) | 119 (45.1) | <0.001† |
| Laboratory tests | |||
| Baseline blood glucose, mmol/L (IQR) | 7.15 (6.30–8.50) | 7.10 (6.10–8.80) | 0.921 |
| HbA1c,% (IQR) | 6.00 (5.50–6.50) | 5.90 (5.50–7.00) | 0.754 |
| HCY, μmol/L (IQR) | 15.43 (11.41–20.05) | 13.25 (9.91–18.20) | 0.068 |
| Platelets, 109/L (IQR) | 176 (150–219) | 199 (160–235) | 0.036 |
| INR (IQR) | 1.04 (0.98–1.12) | 1.02 (0.94–1.09) | 0.022 |
| LDL-C, mmol/L (IQR) | 2.32 (1.83–3.16) | 2.63 (1.95–3.39) | 0.083 |
| eGFR, L/min/1.73 m2 (IQR) | 53.81 (42.04–75.90) | 66.32 (48.59–80.99) | 0.002 |
| Stroke location | |||
| Posterior circulation, n (%) | 33 (36.7) | 84 (31.8) | 0.398 |
| Insula‡, n (%) | 12 (14.1) | 51 (19.6) | 0.255 |
| ICH‡ | 25 (29.4) | 86 (33.1) | 0.530 |
| sICH‡ | 22 (25.9) | 69 (26.5) | 0.905 |
| Mortality§, n (%) | 37 (45.7) | 57 (23.5) | <0.001 |
*Control group.
†P<0.017 was statistically significant.
‡Data were available in 345 patients.
§Data were available in 324 patients.
AF, atrial fibrillation; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HCY, homocysteine; hs-cTnI, high-sensitivity cardiac troponin; ICH, intracranial hemorrhage; INR, international normalized ratio; IQR, interquartile range; LDL-C, low-density lipoprotein; NIHSS, National Institutes of Health Stroke Scale score; OTA, onset-to-admission time; IV rtPA, intravenous recombinant tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage.